Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-212075
Filing Date
2026-05-07
Accepted
2026-05-07 16:25:17
Documents
72
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q whwk-20260331.htm   iXBRL 10-Q 2639437
2 EX-31.1 whwk-ex31_1.htm EX-31.1 17088
3 EX-31.2 whwk-ex31_2.htm EX-31.2 17066
4 EX-32.1 whwk-ex32_1.htm EX-32.1 9469
5 EX-32.2 whwk-ex32_2.htm EX-32.2 9455
  Complete submission text file 0001193125-26-212075.txt   10250722

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT whwk-20260331.xsd EX-101.SCH 1274610
76 EXTRACTED XBRL INSTANCE DOCUMENT whwk-20260331_htm.xml XML 1859516
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38560 | Film No.: 26953941
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)